Allogene Therapeutics (ALLO) Non-Current Assets (2018 - 2026)

Allogene Therapeutics has disclosed Non-Current Assets across 9 years of filings, most recently posting $122.7 million for Q1 2026.

• Non-Current Assets for Q1 2026 came in at $122.7 million, down 43.32% year-over-year; the trailing twelve-month figure through Mar 2026 was $647.8 million (down 30.8% YoY), and the FY2025 annual result was $158.2 million, down 35.53% from the prior year.
• Non-Current Assets came in at $122.7 million for Q1 2026 at Allogene Therapeutics, down from $158.2 million in the prior quarter.
• In the past five years, Non-Current Assets ranged from a high of $508.3 million in Q1 2022 to a low of $122.7 million in Q1 2026.
• The 5-year median for Non-Current Assets is $240.0 million (2023), against an average of $253.4 million.
• Across the five-year window, Non-Current Assets sank 49.48% in 2022 and jumped 33.53% in 2024, its largest moves.
• Allogene Therapeutics' Non-Current Assets stood at $292.8 million in 2022, then sank by 37.24% to $183.7 million in 2023, then soared by 33.53% to $245.3 million in 2024, then slumped by 35.53% to $158.2 million in 2025, then declined by 22.44% to $122.7 million in 2026.
• The last three Non-Current Assets figures came in at $122.7 million (Q1 2026), $158.2 million (Q4 2025), and $179.1 million (Q3 2025), per Business Quant data.